Zeevaart, J. R., Wagener, J., Marjanovic-Painter, B., Sathekge, M., Soni, N., Zinn, C., . . . Smith, S. V. (2013). Production of high specific activity 195mPt-cisplatinum at South African Nuclear Energy Corporation for Phase 0 clinical trials in healthy individual subjects. Journal of labelled compounds & radiopharmaceuticals, 56(9-10), 495-503. https://doi.org/10.1002/jlcr.3091
Chicago Style (17th ed.) CitationZeevaart, Jan Rijn, Judith Wagener, Biljana Marjanovic-Painter, Mike Sathekge, Nischal Soni, Christa Zinn, Gary Perkins, and Suzanne V. Smith. "Production of High Specific Activity 195mPt-cisplatinum at South African Nuclear Energy Corporation for Phase 0 Clinical Trials in Healthy Individual Subjects." Journal of Labelled Compounds & Radiopharmaceuticals 56, no. 9-10 (2013): 495-503. https://doi.org/10.1002/jlcr.3091.
MLA (9th ed.) CitationZeevaart, Jan Rijn, et al. "Production of High Specific Activity 195mPt-cisplatinum at South African Nuclear Energy Corporation for Phase 0 Clinical Trials in Healthy Individual Subjects." Journal of Labelled Compounds & Radiopharmaceuticals, vol. 56, no. 9-10, 2013, pp. 495-503, https://doi.org/10.1002/jlcr.3091.